News
After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...
As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...
With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback